tiprankstipranks
Beroni Group (BNIGF)
OTHER OTC:BNIGF
US Market

Beroni Group (BNIGF) Price & Analysis

5 Followers

BNIGF Stock Chart & Stats

<$0.01
$0.00(0.00%)
At close: 4:00 PM EDT
<$0.01
$0.00(0.00%)

BNIGF FAQ

What was Beroni Group’s price range in the past 12 months?
Beroni Group lowest stock price was <$0.01 and its highest was $0.82 in the past 12 months.
    What is Beroni Group’s market cap?
    Beroni Group’s market cap is $53.05M.
      When is Beroni Group’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Beroni Group’s earnings last quarter?
      Currently, no data Available
      Is Beroni Group overvalued?
      According to Wall Street analysts Beroni Group’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Beroni Group pay dividends?
        Beroni Group does not currently pay dividends.
        What is Beroni Group’s EPS estimate?
        Beroni Group’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Beroni Group have?
        Beroni Group has 33,987,280 shares outstanding.
          What happened to Beroni Group’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Beroni Group?
          Currently, no hedge funds are holding shares in BNIGF
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Beroni Group

            Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products, and a development pipeline targeting oncology and cell therapies. The company has operations in Australia, the United States, China, and Japan.
            Similar Stocks
            Company
            Price & Change
            Follow
            Canaan
            Tesla

            Ownership Overview

            36.41%63.59%
            36.41% Insiders
            ― Other Institutional Investors
            63.59% Public Companies and
            Individual Investors
            Popular Stocks